Alaunos Therapeutics Buyback Yield % Related Terms
Alaunos Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Alaunos Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCRT vs DRMA, MBIO, ELAB: Buyback Yield % Comparison
For the Biotechnology subindustry, Alaunos Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alaunos Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Alaunos Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alaunos Therapeutics (TCRT) has a Buyback Yield % of 0.00 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Alaunos Therapeutics and its competitors. According to the industry distribution chart, Alaunos Therapeutics ranks #999999 out of 741 companies in the Biotechnology industry.
Is Alaunos Therapeutics' Buyback Yield % too high?
Alaunos Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Alaunos Therapeutics ranks #999999 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Buyback Yield % compare to DRMA and MBIO?
According to the Biotechnology industry distribution chart, Alaunos Therapeutics ranks #999999 out of 741 companies for Buyback Yield %. This places Alaunos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.08 — trading 205.9% above its estimated fair value. The current Buyback Yield % is 0.00. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Buyback Yield % is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alaunos Therapeutics (TCRT) Overvalued in 2026?
Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued.
The current stock price of $2.08 is trading 205.9% above its estimated GF Value™ of $0.68.
GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.
Key valuation signals for TCRT:
Buyback Yield %: 0.00
GF Value™: $0.68 vs. price of $2.08 (205.9% above fair value)
No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score
Get the complete analysis for TCRT
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRT has been successfully added to your 
